PVN Winter 2022 Newsletter

WHAT'S INSIDE THIS EDITION
Welcome
IPVC Recap & IPVC 2023 PVP Updates
PVP In The News
PVP Transitions
PVN Publications
Welcome
Welcome to the Winter edition of the Precision Vaccines Network (PVN) Newsletter. The Precision Vaccines Program (PVP) has been busy these past months across a range of collaborative projects, including advancing vaccines against SARS-CoV-2, RSV, and opioid overdose as well as hosting the 3rd biennial International Precision Vaccines Conference (IPVC) which was held 22-23 September 2021.
As the world has made its way through a long and challenging year, we have emerged with renewed appreciation of the importance of our collaborative vaccinology work. We enter 2022 determined to take the lessons we have learned and apply them to the most vexing public health challenges of our lifetime. Please do take some time to explore the various links in this PVN newsletter and reach out to colleagues and potential collaborators. It is often at the interface of distinct fields that unique progress is made!
QUARTERLY NEWSLETTER WINTER 2022 ISSUE


International Precision
Vaccines Conference
After a harrowing eighteen months of a global pandemic, the PVP hosted its 3rd biennial International Precision Vaccines Conference (IPVC) this past September entitled Precision Vaccines: Lessons Learned from the Coronavirus Pandemic. The conference was a successful opportunity that took stock of the lessons learned in our initial efforts to address the COVID-19 challenge. This hybrid conference convened a diverse group of expert speakers to address COVID-19 and precision vaccinology – the application of precision medicine principles to vaccine discovery, development, and delivery.
Key aspects addressed included:
susceptibility to coronavirus
safety and efficacy of coronavirus (CoV) vaccines access to CoV vaccines
vaccine attitudes
how the coronavirus pandemic exacerbated the opioid epidemic
Networking interactions and collaborations nucleated by the IPVC have helped propel this work and we look forward to future progress in these key areas. A special Precision Vaccines Supplement of the journal Clinical Infectious Diseases is in preparation featuring articles from the conference speakers.
2


IPVC 2021 Session Recordings Available
Access the recorded sessions through March 31, 2022.
1. Visit the IPVC virtual lobby
2. Use your IPVC registration login or the following credentials:
Email: [email protected]
Last Name: IPVC2021
3. Scroll down slightly within the virtual lobby to Agenda and choose the date (22 or 23 September). The sessions are listed (continue scrolling to see more).
4. Click Recording next to the session to view. Then click, Play.
A copy of the IPVC booklet will also remain available. Download it by clicking the Booklet icon on the left-hand navigation bar in the virtual lobby.
IPVC 2023
In partnership between Boston Children’s Hospital and Ospedale Pediatrico Bambinu Gesu (OPBG), the 4th Biennial International Precision Vaccines Conference will be held in Rome, Italy! If you are interested in joining the organizing committee, email [email protected]. More details to come.
3


Precision Vaccines Program
Updates
We are proud to report that our NIAID-funded effort to identify adjuvantation systems that enhance coronavirus vaccine efficacy in older adults has borne fruit. A team led by Dr. Etsuro Nanishi and PVP faculty, Dr. David J. Dowling reported that Alum: CpG adjuvantation enabled a receptor binding domain (RBD)-based SARS-CoV-2 protein vaccines with robust immunogenicity and protection was recently published in Science Translational Medicine. This study,
conducted in collaboration with Drs. Peter Hotez and Maria Elena Bottazzi and PVP Director Ofer Levy, provides a scientific rationale for the Corbevax vaccine (Biological E) that has recently been authorized in India.
Partnering with the Mueller Health Foundation, PVP created an educational video for grade and high school students highlighting the global impact of tuberculosis and the current research efforts to develop novel anti-TB antibiotics and vaccines. The video is free to share and use. Click here or on the image to view it.
PVP faculty member, Simon van Haren, PhD, has received a Bill & Melinda Gates Foundation Award on global access adjuvants. This project’s goal is to leverage age specific human in vitro models to assess affordable combination adjuvantation systems for global health vaccines.
The PVP has partnered with Terrapin, the host for the upcoming 18-21 APRIL 2022 World Vaccines Congress in Washington D.C. The PVP will be represented via speakers and attendees. Use code PVP25 for 25% off your ticket.
The PVP is one of the founding members of INSIS, an international consortium partnering to characterize causes of vaccine-associated adverse events of special interest (AESIs), define risk factors for developing AESIs, and inform immunization approaches for those with AESI risk factors.
4


Precision Vaccines Program
Transitions
NIAID adjuvant discovery and Immunophenotyping of a Coronavirus Cohort (IMPACC) studies. In addition to opening new directions for Dr. Ozonoff’s research, this new arrangement further deepens the PVP’s relationship with the Broad Institute.
Please join us in congratulating Drs. Angelidou, Arce & Ozonoff on their new positions!
Asimenia Angelidou MD, PhD has been promoted to Clinical Lead of the PVP. In this capacity, she will partner with PVP faculty across a range of projects involving human cohorts including studies of immunity and immunization in distinct vulnerable populations.
Joann Arce, PhD has been promoted to Lead of the PVP Data Management & Analysis Core (DMAC). In this capacity she will lead the PVP’s data management and bioinformatic portfolio.
Concurrent with his on-going affiliation with the PVP, Al Ozonoff, PhD, has accepted a position at the Sabeti Lab at the Broad Institute, focusing on infectious disease surveillance. Al will continue to provide intellectual support to PVP projects including
5


Precision Vaccines Program
in the Media
04 November 2021, PVP Director, Dr. Ofer Levy presented at TedXBoston regarding application of precision vaccines and the lessons learned from the global pandemic, Set in Boston’s new ‘Quin Club, the talk centered on
themes from the International Precision Vaccines Conference PVP hosted in September 2021.
16 FEB 2022 Dr. Ofer Levy
interviewed by the New York Times about parents and the Covid-19 children 6 months to 5 years of age.
6
01 FEB 2022
Dr. Ofer Levy on CNN discussing EUA for Pfizer vaccine for children age 6 months to 5 years.
13 JAN 2022
Dr. Ofer Levy quoted in Forbes magazine from follow up of TedxBoston event.
02 DEC 2021
Dr. Al Ozonoff quoted in USAToday fact check article on Covid vaccines reporting, specifically the Vaccine Adverse Events Reporting (VAERS).


Precision Vaccines Network
Recent Publications
Precision Vaccines Network members in italics.
BCG vaccination to reduce the impact of COVID-19 in healthcare workers: Protocol for a randomised controlled trial (BRACE trial)
Pittett et.al. (Tobias Kollman, Peter Richmond, Frank Shann, Nigel Curtis)
Machine Learning-Based Single Cell and Integrative Analysis Reveals That Baseline mDC Predisposition Correlates With Hepatitis B Vaccine Antibody Response
Aevermann et.al. (Casey Shannon, Rym Ben-Othman, Robert E Hancock, Scott J Tebbutt, Tobias R Kollmann, Wayne C Koff, Manish Sadarangani)
Modification of innate immune responses to Bordetella pertussis in babies from pertussis vaccinated pregnancies
Rice et.al. (Beate Kampmann)
Humoral and Cellular Response Following Vaccination With the BNT162b2 mRNA COVID- 19 Vaccine in Patients Affected by Primary Immunodeficiencies
Amodio et.al. (Nicola Cotugno, Elena Morrocchi, Paolo Palma, Paolo Rossi)
Activity of mRNA COVID-19 vaccines in patients with lymphoid malignancies
Crombie et.al. (Amy Sherman, Michaël Desjardins, Lindsey R. Baden)
Plasma Adenosine Deaminase (ADA)-1 and -2 Demonstrate Robust Ontogeny Across the First Four Months of Human Life
Odumade et.al. (Oludare A. Odumade, Alec L. Plotkin, Jensen Pak, Olubukola T. Idoko, Matthew A. Pettengill, Tobias R. Kollmann, Al Ozonoff1,2, Beate Kampmann, Ofer Levy, Kinga K. Smolen)
An adjuvant strategy enabled by modulation of the physical properties of microbial ligands expands antigen immunogenicity
Borriello, et.al. (Ivan Zanoni, Francesco Borriello, Etsuro Nanishi, David Dowling, Ofer Levy, Tim O'Meara)
7


JOIN THE PVN
(IT'S FREE!)
FOLLOW THE PVP TW:@PRECVACCINES FB: PRECISIONVACCINES LI: PRECISIONVACCINES